2024
Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy
Ebrahimi H, Battle D, Salgia N, Zengin Z, Dizman N, Meza L, Bergerot C, Barragan-Carrillo R, Hsu J, Castro D, Mercier B, Chawla N, Li X, Tripathi A, Liu S, Chehrazi-Raffle A, Vaishampayan U, Staehler M, Pal S. Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy. Nutrients 2024, 16: 1630. PMID: 38892563, PMCID: PMC11174627, DOI: 10.3390/nu16111630.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaRenal cell carcinomaCell carcinomaDietary modificationSupplement useDiagnosis of renal cell carcinomaFirst-line treatmentSupplement usageSystemic therapyCombination therapyAntineoplastic therapyKetogenic dietCarcinomaCancer therapyMediterranean dietPhysician-patient dialoguePatientsTherapyCancer treatmentGrowing body of evidenceBody of evidenceDietary changesCancerCancer diagnosisCannabidiol
2023
Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma
Dizman N, Govindarajan A, Zengin Z, Meza L, Tripathi N, Sayegh N, Castro D, Chan E, Lee K, Prajapati S, Feng M, Loo V, Pace M, O'Brien S, Bailey E, Barragan-Carrillo R, Chehrazi-Raffle A, Hsu J, Li X, Agarwal N, Pal S. Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 2023, 21: 530-536. PMID: 37495481, DOI: 10.1016/j.clgc.2023.06.004.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaObjective response rateTreatment failureRenal cell carcinomaHazard ratioOverall survivalCell carcinomaMultivariate analysisHigh Cut-OffNivolumab/ipilimumabProspective Randomized StudyBaseline characteristicsRandomized studyClinical outcomesMedian timePreclinical evidenceUnivariate analysisPatientsResponse rateImmune systemInfusion timeStatistical significanceOutcomesCarcinomaInfusionGenomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma
Zengin Z, Govindarajan A, Salgia N, Sayegh N, Tripathi N, Muddasani R, Chehrazi-Raffle A, Feng M, Mercier B, Ladbury C, Hao C, Salgia S, Chawla N, Meza L, Malhotra J, Dizman N, Hsu J, Castro D, Barragan-Carrillo R, Ebrahimi H, Philip E, Chang M, Zhang J, Byron S, Lyou Y, Dorff T, Pal S, Dandapani S. Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma. European Urology Oncology 2023, 6: 447-450. PMID: 36609061, DOI: 10.1016/j.euo.2022.11.006.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaStereotactic body radiation therapyRenal cell carcinomaBody radiation therapyCell carcinomaRadiation therapyClear cell renal cell carcinomaFirst-line treatmentCell renal cell carcinomaStereotactic body radiotherapyKidney cancer patientsOligoprogressive diseaseSystemic treatmentReactive oxygen species pathwayBody radiotherapyCancer patientsTreatment selectionPatientsTreatment changesOxygen species pathwayRadiation treatmentCarcinomaCell proliferationPotential roleRadiotherapy
2022
880 Activation of STAT3 signaling is associated with resistance to immune checkpoint inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC)
Chehrazi-Raffle A, Alcantara M, Dizman N, Tang W, Meza L, Zengin Z, Wang D, Moreira D, Castro D, Govindarajan A, Horsager A, Hsu J, Pal S, Kortylewski M. 880 Activation of STAT3 signaling is associated with resistance to immune checkpoint inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC). 2022, a917-a917. DOI: 10.1136/jitc-2022-sitc2022.0880.Peer-Reviewed Original Research1479P Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC)
Chehrazi-Raffle A, Muddasani R, Dizman N, Hsu J, Meza L, Zengin Z, Malhotra J, Chawla N, Lyou Y, Dorff T, Contente-Cuomo T, Dinwiddie D, McDonald B, Trent J, Murtaza M, Pal S. 1479P Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC). Annals Of Oncology 2022, 33: s1223. DOI: 10.1016/j.annonc.2022.07.1582.Peer-Reviewed Original ResearchFront-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions
Govindarajan A, Castro D, Zengin Z, Salgia S, Patel J, Pal S. Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions. Cancers 2022, 14: 2049. PMID: 35565179, PMCID: PMC9106028, DOI: 10.3390/cancers14092049.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaImmune checkpoint inhibitorsRenal cell carcinomaCheckpoint inhibitorsCell carcinomaMetastatic renal cell carcinoma (mRCC) therapyFront-line settingFront-line therapyRenal cell carcinoma therapyDoublet therapyDurable responsesOverall survivalClinical outcomesCombination therapyTherapy optionsTreatment paradigmTreatment selectionDrug AdministrationCarcinoma therapyTherapyCarcinomaInhibitorsFuture directionsAdministrationVEGFR
2021
1759MO Associations between sarcopenia and gut microbiota in patients (pts) with metastatic renal cell carcinoma (mRCC) and breast cancer (BC)
Zengin Z, Malhotra J, Salgia S, Dizman N, Yost S, Chawla N, Govindarajan A, Hsu J, Salgia N, Bergerot P, Meza L, Chehrazi-Raffle A, Muddasani R, Gillece J, Yuan Y, Highlander S, Pal S. 1759MO Associations between sarcopenia and gut microbiota in patients (pts) with metastatic renal cell carcinoma (mRCC) and breast cancer (BC). Annals Of Oncology 2021, 32: s1211. DOI: 10.1016/j.annonc.2021.08.1704.Peer-Reviewed Original ResearchComplementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma
Zengin ZB, Weipert C, Salgia NJ, Dizman N, Hsu J, Meza L, Chehrazi-Raffle A, Muddasani R, Salgia S, Malhotra J, Chawla N, Philip EJ, Kiedrowski L, Maughan BL, Rathi N, Goel D, Choueiri TK, Agarwal N, Pal SK. Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. Clinical Cancer Research 2021, 27: 4807-4813. PMID: 34130999, DOI: 10.1158/1078-0432.ccr-21-0572.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaCell-free tumor DNARenal cell carcinomaGenomic profilingCell carcinomaTissue-based testingTumor DNA (ctDNA) assessmentClinical Laboratory Improvement AmendmentsActionable alterationsCtDNA profilingCtDNA assessmentPatientsTumor DNAUnique alterationsAlteration frequencyCarcinomaDNA assessmentBloodGreater temporal separationTissueAlterationsConcordancePrevious findingsMutationsConcordance analysis
2020
Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing
Zengin Z, Weipert C, Hsu J, Salgia N, Saam J, Choueiri T, Agarwal N, Pal S. Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing. Annals Of Oncology 2020, 31: s553-s554. DOI: 10.1016/j.annonc.2020.08.773.Peer-Reviewed Original ResearchTivozanib in renal cell carcinoma: a new approach to previously treated disease
Salgia N, Zengin Z, Pal S. Tivozanib in renal cell carcinoma: a new approach to previously treated disease. Therapeutic Advances In Medical Oncology 2020, 12: 1758835920923818. PMID: 32547647, PMCID: PMC7249546, DOI: 10.1177/1758835920923818.Peer-Reviewed Original ResearchPhase III trialsIII trialsMulti-institutional phase III trialVascular endothelial growth factor receptor tyrosine kinasesEarly clinical trialsRenal cell carcinomaManagement of RCCVEGF-TKICell carcinomaClinical trialsTargeted therapyTreatment paradigmMultikinase inhibitorClinical dataFurther trialsGrowth factor receptor tyrosine kinaseTivozanibDisease settingsClinical toolReceptor tyrosine kinasesTrialsRCCTherapyTyrosine kinaseCarcinoma